{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:49:04Z","timestamp":1792784944037,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372762"],"award-info":[{"award-number":["82372762"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073211"],"award-info":[{"award-number":["82073211"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Provincial Medical Innovation Center"},{"name":"Jiangsu Province Capability Improvement Project through Science, Technology and Education, Jiangsu Provincial Medical Key Laboratory"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osimertinib resistance is the main challenge in treating EGFR-mutant lung adenocarcinoma (LUAD). The role of N6-methyladenosine (m6A) modification of circular RNAs (circRNAs) in osimertinib-resistant LUAD remains largely unknown. We used MeRIP-seq and circRNA-seq to screen for potential circRNA candidates that influence osimertinib resistance. It was observed that circRNA LMNB1 (cLMNB1) increased the sensitivity of LUAD to osimertinib in vitro and in vivo. Mechanistically, cLMNB1 acts as a scaffold between fibroblast growth factor receptor 4 (FGFR4) and E3 ubiquitin-protein ligase CBL (c-Cbl), enhancing the ubiquitin-dependent degradation of FGFR4. Furthermore, METTL3 and YTHDF2 are responsible for increased m6A modification levels and decreased cLMNB1 expression in osimertinib-resistant LUAD without affecting its functions. Our findings demonstrate that cLMNB1, mediated by m6A modification, overcomes osimertinib resistance by destabilizing the FGFR4 protein in LUAD. cLMNB1 with an m6A modification site mutation (cLMNB1-mut) could be a promising nucleic acid drug, as it has shown excellent efficacy in osimertinib-resistant preclinical models of LUAD.<\/jats:p>","DOI":"10.1038\/s41419-025-08124-8","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:10:32Z","timestamp":1762787432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The N6-methyladenosine-mediated cLMNB1 degrades FGFR4 to overcome osimertinib resistance in non-small cell lung cancer"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4380-0698","authenticated-orcid":false,"given":"Yuxian","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-8782","authenticated-orcid":false,"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipeng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianfan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6490-1471","authenticated-orcid":false,"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7026-6280","authenticated-orcid":false,"given":"Gaochao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5509-4331","authenticated-orcid":false,"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6569-5956","authenticated-orcid":false,"given":"Feng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"8124_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA A Cancer J Clin"},{"key":"8124_CR2","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","volume":"8","author":"J Qi","year":"2023","unstructured":"Qi J, Li M, Wang L, Hu Y, Liu W, Long Z, et al. National and subnational trends in cancer burden in China, 2005\u201320: an analysis of national mortality surveillance data. Lancet Public Health. 2023;8:e943\u201355.","journal-title":"Lancet Public Health"},{"key":"8124_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41\u201350.","journal-title":"N Engl J Med"},{"key":"8124_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jtho.2019.11.005","volume":"15","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Yu HA. The evolving landscape of resistance to osimertinib. J Thorac Oncol. 2020;15:18\u201321.","journal-title":"J Thorac Oncol"},{"key":"8124_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/0008-5472.CAN-18-1281","volume":"79","author":"A Murtuza","year":"2019","unstructured":"Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ, et al. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res. 2019;79:689\u201398.","journal-title":"Cancer Res"},{"key":"8124_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102557","volume":"116","author":"Z Zalaquett","year":"2023","unstructured":"Zalaquett Z, Catherine Rita Hachem M, Kassis Y, Hachem S, Eid R, Raphael Kourie H, et al. Acquired resistance mechanisms to osimertinib: the constant battle. Cancer Treat Rev. 2023;116:102557.","journal-title":"Cancer Treat Rev"},{"key":"8124_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41580-020-0243-y","volume":"21","author":"LL Chen","year":"2020","unstructured":"Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21:475\u201390.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8124_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01620-x","volume":"21","author":"H Lin","year":"2022","unstructured":"Lin H, Wang Y, Wang P, Long F, Wang T. Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance. Mol Cancer. 2022;21:148.","journal-title":"Mol Cancer"},{"key":"8124_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.731561","volume":"11","author":"K Li","year":"2021","unstructured":"Li K, Gao S, Ma L, Sun Y, Peng ZY, Wu J, et al. Stimulation of Let-7 maturation by metformin improved the response to tyrosine kinase inhibitor therapy in an m6A dependent manner. Front Oncol. 2021;11:731561.","journal-title":"Front Oncol"},{"key":"8124_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01811-0","volume":"22","author":"K Li","year":"2023","unstructured":"Li K, Peng ZY, Wang R, Li X, Du N, Liu DP, et al. Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7. Mol Cancer. 2023;22:103.","journal-title":"Mol Cancer"},{"key":"8124_CR11","doi-asserted-by":"crossref","unstructured":"Song H, Liu D, Wang L, Liu K, Chen C, Wang L, et al. Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma. Mol Cancer. 2022;21:43.","DOI":"10.1186\/s12943-022-01519-7"},{"key":"8124_CR12","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","volume":"186","author":"E Nolan","year":"2023","unstructured":"Nolan E, Lindeman GJ, Visvader JE. Deciphering breast cancer: from biology to the clinic. Cell. 2023;186:1708\u201328.","journal-title":"Cell"},{"key":"8124_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116\u201329.","journal-title":"Nat Rev Cancer"},{"key":"8124_CR14","doi-asserted-by":"crossref","unstructured":"Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2:62ra93.","DOI":"10.1126\/scitranslmed.3001451"},{"key":"8124_CR15","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"Jin H, Shi Y, Lv Y, Yuan S, Ramirez CFA, Lieftink C, et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021;595:730\u20134.","journal-title":"Nature"},{"key":"8124_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.lungcan.2019.02.007","volume":"131","author":"A Quintanal-Villalonga","year":"2019","unstructured":"Quintanal-Villalonga A, Molina-Pinelo S, Yag\u00fce P, Marrugal \u00c1, Ojeda-M\u00e1rquez L, Suarez R, et al. FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. Lung Cancer. 2019;131:112\u201321.","journal-title":"Lung Cancer"},{"key":"8124_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1001\/jama.2020.25127","volume":"325","author":"S Joffe","year":"2021","unstructured":"Joffe S. Evaluating SARS-CoV-2 vaccines after emergency use authorization or licensing of initial candidate vaccines. JAMA. 2021;325:221.","journal-title":"JAMA"},{"key":"8124_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12951-022-01478-7","volume":"20","author":"SH Kiaie","year":"2022","unstructured":"Kiaie SH, Majidi Zolbanin N, Ahmadi A, Bagherifar R, Valizadeh H, Kashanchi F, et al. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects. J Nanobiotechnol. 2022;20:276.","journal-title":"J Nanobiotechnol"},{"key":"8124_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.canlet.2017.08.030","volume":"408","author":"S Wang","year":"2017","unstructured":"Wang S, Sun C, Li J, Zhang E, Ma Z, Xu W, et al. Roles of RNA methylation by means of N6-methyladenosine (m6A) in human cancers. Cancer Lett. 2017;408:112\u201320.","journal-title":"Cancer Lett"},{"key":"8124_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107641","volume":"31","author":"G Di Timoteo","year":"2020","unstructured":"Di Timoteo G, Dattilo D, Centr\u00f3n-Broco A, Colantoni A, Guarnacci M, Rossi F, et al. Modulation of circRNA metabolism by m6A modification. Cell Rep. 2020;31:107641.","journal-title":"Cell Rep"},{"key":"8124_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12651-2","volume":"10","author":"RX Chen","year":"2019","unstructured":"Chen RX, Chen X, Xia LP, Zhang JX, Pan ZZ, Ma XD, et al. N6-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis. Nat Commun. 2019;10:4695.","journal-title":"Nat Commun"},{"key":"8124_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.canlet.2021.08.007","volume":"520","author":"T Wang","year":"2021","unstructured":"Wang T, Liu Z, She Y, Deng J, Zhong Y, Zhao M, et al. A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis. Cancer Lett. 2021;520:321\u201331.","journal-title":"Cancer Lett"},{"key":"8124_CR23","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.molcel.2019.02.034","volume":"74","author":"OH Park","year":"2019","unstructured":"Park OH, Ha H, Lee Y, Boo SH, Kwon DH, Song HK, et al. Endoribonucleolytic cleavage of m6A-containing RNAs by RNase P\/MRP complex. Mol Cell. 2019;74:494\u2013507.e8.","journal-title":"Mol Cell"},{"key":"8124_CR24","doi-asserted-by":"publisher","first-page":"669","DOI":"10.4161\/rna.28829","volume":"11","author":"X Wang","year":"2014","unstructured":"Wang X, He C. Reading RNA methylation codes through methyl-specific binding proteins. RNA Biol. 2014;11:669\u201372.","journal-title":"RNA Biol"},{"key":"8124_CR25","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.aax3769","volume":"366","author":"C Pohl","year":"2019","unstructured":"Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science. 2019;366:818\u201322.","journal-title":"Science"},{"key":"8124_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.tcb.2013.12.003","volume":"24","author":"G Kleiger","year":"2014","unstructured":"Kleiger G, Mayor T. Perilous journey: a tour of the ubiquitin\u2013proteasome system. Trends Cell Biol. 2014;24:352\u20139.","journal-title":"Trends Cell Biol"},{"key":"8124_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/cr.2016.39","volume":"26","author":"KN Swatek","year":"2016","unstructured":"Swatek KN, Komander D. Ubiquitin modifications. Cell Res. 2016;26:399\u2013422.","journal-title":"Cell Res"},{"key":"8124_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cell.2010.03.029","volume":"141","author":"W Zeng","year":"2010","unstructured":"Zeng W, Sun L, Jiang X, Chen X, Hou F, Adhikari A, et al. Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity. Cell. 2010;141:315\u201330.","journal-title":"Cell"},{"key":"8124_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41392-023-01561-x","volume":"8","author":"D Niu","year":"2023","unstructured":"Niu D, Wu Y, Lian J. Circular RNA vaccine in disease prevention and treatment. Sig Transduct Target Ther. 2023;8:341.","journal-title":"Sig Transduct Target Ther"},{"key":"8124_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202400307","volume":"36","author":"S Xu","year":"2024","unstructured":"Xu S, Xu Y, Solek NC, Chen J, Gong F, Varley AJ, et al. Tumor-tailored ionizable lipid nanoparticles facilitate IL-12 circular RNA delivery for enhanced lung cancer immunotherapy. Adv Mater. 2024;36:2400307.","journal-title":"Adv Mater"},{"key":"8124_CR31","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328.","journal-title":"N Engl J Med"},{"key":"8124_CR32","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240\u20137.","journal-title":"Clin Cancer Res"},{"key":"8124_CR33","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41392-020-00375-5","volume":"5","author":"J Xu","year":"2020","unstructured":"Xu J, Ji L, Liang Y, Wan Z, Zheng W, Song X, et al. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Sig Transduct Target Ther. 2020;5:298.","journal-title":"Sig Transduct Target Ther"},{"key":"8124_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/cas.15177","volume":"113","author":"S Liu","year":"2022","unstructured":"Liu S, Jiang Z, Xiao P, Li X, Chen Y, Tang H, et al. Hsa_circ_0005576 promotes osimertinib resistance through the miR-512-5p\/IGF1R axis in lung adenocarcinoma cells. Cancer Sci. 2022;113:79\u201390.","journal-title":"Cancer Sci"},{"key":"8124_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13046-022-02383-5","volume":"41","author":"SL Chan","year":"2022","unstructured":"Chan SL, Schuler M, Kang YK, Yen CJ, Edeline J, Choo SP, et al. A first-in-human phase 1\/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. J Exp Clin Cancer Res. 2022;41:189.","journal-title":"J Exp Clin Cancer Res"},{"key":"8124_CR36","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","volume":"24","author":"S Pant","year":"2023","unstructured":"Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol. 2023;24:925\u201335.","journal-title":"Lancet Oncol"},{"key":"8124_CR37","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/med.21288","volume":"34","author":"M Katoh","year":"2014","unstructured":"Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics: CANCER BIOLOGY AND THERAPEUTICS ON FGF RECEPTORS. Med Res Rev. 2014;34:280\u2013300.","journal-title":"Med Res Rev"},{"key":"8124_CR38","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1158\/2159-8290.CD-23-0383","volume":"13","author":"NM Sodir","year":"2023","unstructured":"Sodir NM, Pathria G, Adamkewicz JI, Kelley EH, Sudhamsu J, Merchant M, et al. SHP2: a pleiotropic target at the interface of cancer and its microenvironment. Cancer Discov. 2023;13:2339\u201355.","journal-title":"Cancer Discov"},{"key":"8124_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jhep.2023.02.036","volume":"79","author":"M Xie","year":"2023","unstructured":"Xie M, Lin Z, Ji X, Luo X, Zhang Z, Sun M, et al. FGF19\/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. J Hepatol. 2023;79:109\u201325.","journal-title":"J Hepatol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08124-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:10:34Z","timestamp":1762787434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08124-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8124"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08124-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"818"}}